Triple therapy versus dual or monotherapy with long-acting bronchodilators for chronic obstructive pulmonary disease. A systematic review and meta-analysis
Rationale: There is uncertainty on the use of using triple therapy (inhaled
corticosteroids/long-acting β-agonist/long-acting muscarinic antagonist) inhaler therapy for …
corticosteroids/long-acting β-agonist/long-acting muscarinic antagonist) inhaler therapy for …
[HTML][HTML] Triple therapy versus dual bronchodilation and inhaled corticosteroids/long-acting β-agonists in COPD: accumulating evidence from network meta-analyses
M Cazzola, L Calzetta, P Rogliani, MG Matera - Pulmonary Therapy, 2019 - Springer
Guidelines are mainly based on evidence of well-designed randomized controlled trials
(RCTs), but there are limitations to the transferability of conclusions of RCTs to usual care …
(RCTs), but there are limitations to the transferability of conclusions of RCTs to usual care …
Triple therapy for the management of COPD: a review
K Gaebel, RA McIvor, F Xie, G Blackhouse… - COPD: Journal of …, 2011 - Taylor & Francis
Triple therapy for COPD consists of a long-acting anti-cholinergic bronchodilator, a long-
acting beta-agonist bronchodilator, and an inhaled corticosteroid. Guidelines from the …
acting beta-agonist bronchodilator, and an inhaled corticosteroid. Guidelines from the …
Triple therapy versus single and dual long-acting bronchodilator therapy in COPD: a systematic review and meta-analysis
M Cazzola, P Rogliani, L Calzetta… - European Respiratory …, 2018 - Eur Respiratory Soc
We performed a meta-analysis to compare the impact of triple combination therapy with
inhaled corticosteroids (ICS), long-acting β2-agonists (LABAs) and long-acting muscarinic …
inhaled corticosteroids (ICS), long-acting β2-agonists (LABAs) and long-acting muscarinic …
Triple combinations in chronic obstructive pulmonary disease–is three better than two?
M Cazzola, MG Matera - Expert Opinion on Pharmacotherapy, 2014 - Taylor & Francis
A growing body of evidence suggests that triple therapy with an antimuscarinic agent, a long-
acting β2-agonist, and an inhaled corticosteroid is efficacious in patients with more severe …
acting β2-agonist, and an inhaled corticosteroid is efficacious in patients with more severe …
Single-inhaler triple versus dual bronchodilator therapy in COPD: real-world comparative effectiveness and safety
Purpose Randomized trials report that single-inhaler triple therapy is more effective than
dual bronchodilators at reducing exacerbations in patients with chronic obstructive …
dual bronchodilators at reducing exacerbations in patients with chronic obstructive …
Dual bronchodilation vs triple therapy in the “real-life” COPD DACCORD study
R Buhl, CP Criée, P Kardos… - … Journal of Chronic …, 2018 - Taylor & Francis
Background No observational studies have evaluated the “real-world” effectiveness of dual
bronchodilation comprising a long-acting β2-agonist plus a long-acting muscarinic …
bronchodilation comprising a long-acting β2-agonist plus a long-acting muscarinic …
Dual bronchodilator therapy for chronic obstructive pulmonary disease: evidence for the efficacy and safety of fixed dose combination treatments in the setting of …
SD Deas, N Huprikar - Current Opinion in Pulmonary Medicine, 2018 - journals.lww.com
New guidelines emphasize combination bronchodilators as a mainstay of therapy for many
patients with symptomatic COPD and there are several new combination bronchodilator …
patients with symptomatic COPD and there are several new combination bronchodilator …
Triple therapy in COPD: what we know and what we don't
PMA Calverley, H Magnussen… - COPD: Journal of …, 2017 - Taylor & Francis
Triple inhaled therapy for chronic obstructive pulmonary disease (COPD) consists of an
inhaled corticosteroid (ICS), a long-acting β2-agonist (LABA) and a long-acting muscarinic …
inhaled corticosteroid (ICS), a long-acting β2-agonist (LABA) and a long-acting muscarinic …
Beyond dual bronchodilation–triple therapy, when and why
M Cazzola, P Rogliani, R Laitano… - … Journal of Chronic …, 2022 - Taylor & Francis
Although pharmacological treatment of COPD is codified in different guidelines and strategy
documents, there is abundant evidence of discrepancy between what they suggest and what …
documents, there is abundant evidence of discrepancy between what they suggest and what …